Combination Radiopharmaceutical Therapy and External Beam Radiotherapy
放射药物治疗与外照射放射治疗的联合治疗
基本信息
- 批准号:10473785
- 负责人:
- 金额:$ 54.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-03 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAreaBindingBiological Response Modifier TherapyCancer PatientCharacteristicsClinical TrialsComputer softwareDataDevelopmentDigital Imaging and Communications in MedicineDiseaseDisseminated Malignant NeoplasmDoseElementsEndocrinologyEngineeringEpithelialFDA approvedGrantImageIndustrializationIntellectual PropertyLeadMalignant NeoplasmsMalignant neoplasm of thyroidMapsMedical OncologyMethodologyMethodsModalityNeoplasm MetastasisNormal tissue morphologyOrganOutputPatientsPharmacologic SubstancePhasePhase I Clinical TrialsPhysicsRadiationRadiation OncologyRadiation ToleranceRadiation therapyRadioactiveRadioactive IodineRadiopharmaceuticalsRecording of previous eventsSafetySoftware ToolsSolidSolid NeoplasmSystemTherapeuticThinkingTissuesToxic effectTreatment outcomeUnited States National Institutes of HealthUniversitiesWidespread DiseaseWorkbasecancer cellcancer therapycell killingchemotherapyclinical implementationcloud baseddosimetryexperienceimprovedindividual patientindustry partnerinterestmedical schoolsmembermulti-arm trialneoplastic cellnovelradiation deliveryradioiodine therapyreconstructionsafety and feasibilitysingle photon emission computed tomographysoftware developmentsuccesstargeted deliverythyroid neoplasmtooltreatment optimizationtreatment planningtumoruptake
项目摘要
Problem: Treatment options for late stage metastatic cancer are limited. External beam radiotherapy (XRT) is
generally effective, but limited against widespread disease or tumors adjacent to radiosensitive tissue.
Radiopharmaceutical therapy (RPT), a therapeutic modality with origins in radioiodine therapy of thyroid cancer,
has become an effective alternative to chemo- and biologic therapy. RPT is complementary to XRT. It exploits
pharmaceuticals that bind to tumor cells to deliver targeted radiation. It targets metastases while providing a
radiation boost to tumors. Combining XRT with RPT (e.g., as opposed to chemotherapy) allows a precise
determination of potential toxicity to normal organs since both modalities involve radiation whose effects on
normal tissues can be quantified and predicted by treatment planning.
Our solution to treating widespread metastases is to commercialize enhanced dosimetric tools that will make
combination XRT and RPT (CXRPT) a routine cancer treatment. We will assess safety and feasibility of CXRPT
in thyroid cancer patients who are not likely to be effectively treated with radioiodine alone and who are good
candidates for CXRPT. Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid) will provide the methodology
and software for CXRPT; Johns Hopkins University, School of Medicine will implement CXRPT.
Specific aims:
1. Conduct a phase I clinical trial of CXRPT in differentiated thyroid cancer patients.
Establish safety of CXRPT, provide a rationale for a larger multi-arm trial that will demonstrate greater efficacy
over current treatment.
2. Implement the CXRPT methodology in a cloud-based software package, 3D-RD-X; validate results from the
cloud-based package against the localized package.
3. Obtain data needed for eventual FDA clearance of 3D-RD-X.
Aims 2 and 3 are essential steps towards generating a commercially viable software package that will enable
widespread implementation of CXRPT.
This proposal will introduce a novel treatment combination applicable to every cancer for which RPT exists
or may be developed. The investigative team is already highly collaborative. Rapid’s founders have previously
implemented advanced dosimetry for thyroid cancer patients and have a long record in this area. This proposal
will enable a fundamentally new treatment paradigm that leverages widely available radiotherapy treatment with
ongoing development of novel RPTs. We expect widespread implementation and commercial interest once we
have demonstrated feasibility and provided the software tool to implement this treatment approach.
问题:晚期转移性癌症的治疗选择有限。体外放射治疗(XRT)
通常有效,但对邻近放射敏感组织的广泛疾病或肿瘤有限。
放射性药物治疗(RPT)是一种起源于甲状腺癌放射性碘治疗的治疗方式,
已经成为化疗和生物治疗的有效替代方案。RPT是XRT的补充。中国可以利用
与肿瘤细胞结合以提供靶向辐射的药物。它靶向转移,同时提供
对肿瘤的辐射增强。将XRT与RPT结合起来(例如,与化疗相反)允许精确的
确定对正常器官的潜在毒性,因为这两种方式都涉及辐射,
可以通过治疗计划来量化和预测正常组织。
我们治疗广泛转移的解决方案是商业化增强剂量测定工具,
联合XRT和RPT(CXRPT)是一种常规的癌症治疗方法。我们将评估CXRPT的安全性和可行性
在甲状腺癌患者中,仅用放射性碘不太可能有效治疗,
CXRPT的候选人。放射性药物成像和剂量测定有限责任公司(Rapid)将提供方法
和软件;约翰霍普金斯大学医学院将实施CXRPT。
具体目标:
1.开展CXRPT在分化型甲状腺癌患者中的I期临床试验。
确定CXRPT的安全性,为证明更大疗效的更大规模多组试验提供依据
目前的治疗。
2.在基于云的软件包3D-RD-X中实施CXRPT方法;验证
基于云的软件包与本地化软件包进行比较。
3.获得FDA最终批准3D-RD-X所需的数据。
目标2和目标3是产生商业上可行的软件包的基本步骤,
CXRPT的广泛实施。
该提案将引入一种适用于RPT存在的每种癌症的新型治疗组合
或者可以被开发。调查小组已经高度合作。Rapid的创始人此前曾
为甲状腺癌患者实施了先进的剂量测定,并在该领域拥有长期记录。这项建议
将实现一种全新的治疗模式,利用广泛可用的放射治疗,
正在开发新的RPT。我们期待广泛的实施和商业利益,一旦我们
已经证明了可行性,并提供了软件工具来实现这种治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Francois Hobbs其他文献
Robert Francois Hobbs的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Francois Hobbs', 18)}}的其他基金
Macro-to-micro (M2µ) Activity Apportionment for αRPT
αRPT 的宏观到微观 (M2µ) 活动分配
- 批准号:
10713712 - 财政年份:2023
- 资助金额:
$ 54.8万 - 项目类别:
Combination Radiopharmaceutical Therapy and External Beam Radiotherapy
放射药物治疗与外照射放射治疗的联合治疗
- 批准号:
10252753 - 财政年份:2020
- 资助金额:
$ 54.8万 - 项目类别:
Combination Radiopharmaceutical Therapy and External Beam Radiotherapy
放射药物治疗与外照射放射治疗的联合治疗
- 批准号:
10668390 - 财政年份:2020
- 资助金额:
$ 54.8万 - 项目类别:
Modeling Targeted Alpha Particle Therapy of Cancer
癌症靶向阿尔法粒子治疗建模
- 批准号:
8295112 - 财政年份:2012
- 资助金额:
$ 54.8万 - 项目类别:
Modeling Targeted Alpha Particle Therapy of Cancer
癌症靶向阿尔法粒子治疗建模
- 批准号:
8468664 - 财政年份:2012
- 资助金额:
$ 54.8万 - 项目类别:
Modeling Targeted Alpha Particle Therapy of Cancer
癌症靶向阿尔法粒子治疗建模
- 批准号:
8658040 - 财政年份:2012
- 资助金额:
$ 54.8万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 54.8万 - 项目类别:
Research Grant